SEC Comment Letter 0000000000-24-003828 to Revolution Medicines, Inc. (RVMD, RVMDW) (CIK 0001628171) (RVMD)
Revolution Medicines, Inc. (RVMD, RVMDW) (CIK 0001628171)
Date: April 9, 2024 · CIK: 0001628171 · Accession: 0000000000-24-003828
AI Filing Summary & Sentiment
File numbers found in text: 001-39219
Letter
United States securities and exchange commission logo April 9, 2024 Jack Anders Chief Financial Officer Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, CA 94063 Re:Revolution Medicines, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-39219 Dear Jack Anders: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe this comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10-K for Fiscal Year Ended December 31, 2023 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Research and development expenses, page 91 1.We note from the pipeline table on page 9 that you have multiple products that are in clinical development. Please revise future filings to disclose the costs incurred during each period presented for each of your key research and development product candidates. If you do not track your research and development costs by project, disclose that fact and explain why you do not maintain and evaluate research and development costs by project. Also, revise to provide other quantitative and qualitative disclosures that give more transparency as to the type of research and development expenses incurred (i.e., by nature or type of expense) which should reconcile to total research and development expenses on your Statements of Operations. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameJack Anders Comapany NameRevolution Medicines, Inc. April 9, 2024 Page 2 FirstName LastName Jack Anders Revolution Medicines, Inc. April 9, 2024 Page 2 Please contact Lynn Dicker at 202-551-3616 or Tara Harkins at 202-551-3639 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
April 9, 2024
Jack Anders
Chief Financial Officer
Revolution Medicines, Inc.
700 Saginaw Drive
Redwood City, CA 94063
Re:Revolution Medicines, Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
File No. 001-39219
Dear Jack Anders:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe
this comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K for Fiscal Year Ended December 31, 2023
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Research and development expenses, page 91
1.We note from the pipeline table on page 9 that you have multiple products that are in
clinical development. Please revise future filings to disclose the costs incurred during each
period presented for each of your key research and development product candidates. If
you do not track your research and development costs by project, disclose that fact and
explain why you do not maintain and evaluate research and development costs by project.
Also, revise to provide other quantitative and qualitative disclosures that give more
transparency as to the type of research and development expenses incurred (i.e., by nature
or type of expense) which should reconcile to total research and development expenses on
your Statements of Operations.
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
FirstName LastNameJack Anders
Comapany NameRevolution Medicines, Inc.
April 9, 2024 Page 2
FirstName LastName
Jack Anders
Revolution Medicines, Inc.
April 9, 2024
Page 2
Please contact Lynn Dicker at 202-551-3616 or Tara Harkins at 202-551-3639 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences